UK's Hikma tightens annual profit outlook as branded medicines drive growth
Thursday, 5 November 2026 | Global Edition Hikma Pharmaceuticals narrowed its 2026 full‑year operating profit guidance to $740m–$760m, driven by strong branded medicines growth in the Middle East and North Africa, while injectables stabilise and revenue growth of 2%–4% is maintained. Nov 5 (Reuters) - Britain's Hikma…